| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 10/24/2006 | US7125895 Arylalkylamine compounds as chemokine receptor antagonists for therapy and prevention of diseases such as arthritis or rheumatic diseases |
| 10/24/2006 | US7125892 Aryl aniline β2 adrenergic receptor agonists |
| 10/24/2006 | US7125891 Such as (1-((2,3-dihydro-2-(4-propyl-1H-imidazol-2-yl)-1H-indol-1 -yl)carbonyl)propyl)-carbamate; for inactivation of cholecystokinins |
| 10/24/2006 | US7125890 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors |
| 10/24/2006 | US7125887 Pyrrolidine modulators of CCR5 chemokine receptor activity |
| 10/24/2006 | US7125885 2-substituted-9-trifluoromethyl-11-methyl-1,2,3,4,5,11-hexahydro-6H-pyrido(3,2-b)carbazole compounds as melanin-concentrating hormone receptor modulators for treatment of G-protein coupled receptor-mediated disorders such as eating disorders, obesity, anxiety disorders and mood disorders |
| 10/24/2006 | US7125884 N-but-3-enyl norbuprenorphine and its use as analgesic |
| 10/24/2006 | US7125881 Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives |
| 10/24/2006 | US7125878 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 10/24/2006 | US7125877 Brain disorders; psychological disorders; central nervous system disorders; antidiabetic agents; hypotensive agents |
| 10/24/2006 | US7125874 Optically active 5H-pyrrolo[3,4-b] pyrazine derivative, its preparation and pharmaceutical compositions containing same |
| 10/24/2006 | US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 10/24/2006 | US7125839 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 10/24/2006 | US7125838 Peptides containing N-substituted L-amino acids for preventing β-strand association |
| 10/24/2006 | US7125688 A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and a protein |
| 10/24/2006 | US7125687 Presenilin enhancers assays |
| 10/24/2006 | US7125564 Glycyrrhizin complex |
| 10/24/2006 | US7125560 Pharmaceutical composition of topiramate |
| 10/24/2006 | CA2332915C Compositions comprising gaba analogs and caffeine |
| 10/24/2006 | CA2274183C Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
| 10/24/2006 | CA2264598C 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives |
| 10/24/2006 | CA2249402C Benzopyran derivatives having leukotriene-antagonistic action |
| 10/24/2006 | CA2227711C Thioctic acid metabolites and methods of use thereof |
| 10/24/2006 | CA2208199C Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| 10/24/2006 | CA2195663C Dihydrobenzofuranes |
| 10/24/2006 | CA2168023C Vasoconstrictive substituted aryloxyalkyl diamines |
| 10/24/2006 | CA2167584C Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| 10/19/2006 | WO2006110668A1 Compounds which inhibit beta-secretase activity and methods of use thereof |
| 10/19/2006 | WO2006110483A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 10/19/2006 | WO2006109876A1 Agent for treating involuntary movement |
| 10/19/2006 | WO2006109867A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVE OR MEDICALLY ACCEPTABLE SALT THEREOF |
| 10/19/2006 | WO2006109846A1 Triazole derivative and the use thereof |
| 10/19/2006 | WO2006109817A1 1,4-substituted piperazine derivative |
| 10/19/2006 | WO2006109729A1 Pyridylmethylsulfone derivative |
| 10/19/2006 | WO2006109671A1 Crystals of morphinan derivative and process for producing the same |
| 10/19/2006 | WO2006109284A1 Use of filamentous hemagglutinin for the treatment of cognitive dysfunction and neurodegenerative disorders |
| 10/19/2006 | WO2006109190A1 Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders |
| 10/19/2006 | WO2006109164A2 A method for preventing, delaying or reverting abnormal amyloid deposition |
| 10/19/2006 | WO2006108880A1 S-adenosyl-l-methionine for regulating behavioral disorders in pets |
| 10/19/2006 | WO2006108800A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 10/19/2006 | WO2006108789A1 Novel enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors |
| 10/19/2006 | WO2006108773A1 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |
| 10/19/2006 | WO2006108701A1 3- (1,2,4-triazol-3ylalkyl) azabriclo (3.1.0) hexane derivatives as modulators of dopamine d3 receptors |
| 10/19/2006 | WO2006108700A1 3-triazolylthioalkyl-3-azabicyclo (3 - 1 - o) hexanes and their use as dopamine d3 receptor ligands |
| 10/19/2006 | WO2006108689A2 Process for preparing bicyclic compounds |
| 10/19/2006 | WO2006108666A1 Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases |
| 10/19/2006 | WO2006108591A1 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands |
| 10/19/2006 | WO2006108565A1 Spirocyclic cyclohexane derivatives for use in the treatment of substance dependency |
| 10/19/2006 | WO2006108262A2 Regulation of neurotrophins |
| 10/19/2006 | WO2006087577A3 Inhibition or treatment of dyskinesia |
| 10/19/2006 | WO2006068932A3 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| 10/19/2006 | WO2006064336A3 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 10/19/2006 | WO2006050476A3 Pyrimidine derivatives as ion channel modulators and methods of use |
| 10/19/2006 | WO2006037482A3 Compositions and methods for treating cognitive disorders |
| 10/19/2006 | WO2005103041A3 Treatment of cns disorders using cns target modulators |
| 10/19/2006 | US20060235239 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 10/19/2006 | US20060235231 Histone deacetylase inhibitors |
| 10/19/2006 | US20060235072 Potassium channel opener |
| 10/19/2006 | US20060235058 Substituted 5-membered ring compounds and their use |
| 10/19/2006 | US20060235057 Phenyl compounds |
| 10/19/2006 | US20060235054 e.g. 3-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)imidazole-2-thione; immunomodulating and cytokine-release-inhibiting action; antiinflammatory agent |
| 10/19/2006 | US20060235049 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders |
| 10/19/2006 | US20060235043 Antiviral Pyrazolopyridine Compounds |
| 10/19/2006 | US20060235027 Inhibitors of cdc25 phosphatases |
| 10/19/2006 | US20060235026 Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists |
| 10/19/2006 | US20060235025 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 10/19/2006 | US20060235023 Inhibitors of macrophage migration inhibitory factor and methods for indentifying the same |
| 10/19/2006 | US20060235019 Substituted quinazolinone compounds |
| 10/19/2006 | US20060235015 Pyrrole-2,5-dione derivatives as liver x receptor modulators |
| 10/19/2006 | US20060235012 Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| 10/19/2006 | US20060235011 N-cyclopropylmethyl-N-7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethylpyrazolo[1,5-a]pyridin-3-yl-N-tetrahydro-2H-4-pyranylmethylamine; depressive symptom, mania, anxiety, general anxiety disorder, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, Tourette's syndrome |
| 10/19/2006 | US20060235004 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands |
| 10/19/2006 | US20060235003 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives |
| 10/19/2006 | US20060235000 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 10/19/2006 | US20060234991 Combinations for the treatment of immunoinflammatory disorders |
| 10/19/2006 | US20060234987 Neuroprotective benzo 1 3 oxathiol 2 ones |
| 10/19/2006 | US20060234975 Use of adenosine receptor agonists in therapy |
| 10/19/2006 | US20060234968 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 10/19/2006 | US20060234955 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| 10/19/2006 | US20060234949 Adduct of topiramate and tramadol hydrochloride and uses thereof |
| 10/19/2006 | US20060234946 Use of telmisartan for the prevention and treatment of vascular headache |
| 10/19/2006 | US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis |
| 10/19/2006 | US20060234922 Remedy for corneal failure |
| 10/19/2006 | US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia |
| 10/19/2006 | US20060234344 Protein kinases |
| 10/19/2006 | US20060234329 Method for determining the antiradical defense potential and use thereof, in particular in veterinary and human preventive therapeutics |
| 10/19/2006 | US20060233896 Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, Cistanche tubulosa (Schenk.) Wight, process of making the same, and uses of the same |
| 10/19/2006 | US20060233890 Method for treating a mammal by administration of a compound having the ability to release CO |
| 10/19/2006 | US20060233885 Analgesic agent for newborn or fetal subjects |
| 10/19/2006 | US20060233833 Novel uses of parapoxvirus preparations |
| 10/19/2006 | US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/19/2006 | US20060233771 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 10/19/2006 | US20060233746 N-terminally chemically modified protein compositions and methods |
| 10/19/2006 | US20060233719 Delivery of antidepressants through an inhalation route |
| 10/19/2006 | US20060233718 heating drugs used for the treatment of anxiety or insomnia, coated on solid supports to form vapors and condensing the vapor to form aerosols comprising microstructure particles of the drugs |
| 10/19/2006 | DE112004001502T5 Neurobeschützende und Anti-Proliferationsverbindungen Neurobeschützende and anti-proliferative compounds |
| 10/19/2006 | DE102005017799A1 Use of heparin- or heparin derivative to treat illness associated with neurite plasticity or -growth defects, modulates interaction between Nogo receptor and ligands |
| 10/19/2006 | DE102005016460A1 Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit Spriocyclische cyclohexane derivatives for the treatment of substance dependence |
| 10/19/2006 | CA2605384A1 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |
| 10/19/2006 | CA2604516A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |